Beneficial E. coli helps heal ulcerative colitis

The emerging science of the human microbiome and modulation of the immune system by introducing specific strains of probiotic flora into the gut and other microbial ecosystems is one of the most fascinating and promising developments in medicine. A study published some time back in the journal GUT (An International Journal of Gastroenterology and Hepatology) is among a number of investigations into the benefit of Escherichia coli Nissle 1917 in stimulating the immune system to heal ulcerative colitis:

"We compared the efficacy in maintaining remission of the probiotic preparation Escherichia coli Nissle 1917 and established therapy with mesalazine in patients with ulcerative colitis."

The authors assigned 327 patients to receive either the Escherichia coli Nissle 1917 or mesalazine and evaluated the outcomes according to clinical, endoscopic  and histologic (tissue microscopic) indices over a twelve month period. Mesalazine is an anti-inflammatory medication administered by suppository that is not without concerns, and a suppressive palliation at best.

"The primary aim of the study was to confirm equivalent efficacy of the two drugs in the prevention of relapses."

Wouldn't it be better to stimulate the immune system to express healthier regulation if possible? The data established this notable conclusion:

"The probiotic drug E coli Nissle 1917 shows efficacy and safety in maintaining remission equivalent to the gold standard mesalazine in patients with ulcerative colitis. The effectiveness of probiotic treatment further underlines the pathogenetic significance of the enteric flora."

This is but one example among many more you'll be hearing about in this fascinating and promising area of research and clinical application.